Last updated: February 19, 2026
Selpercatinib (development code: LOXO-292) is a targeted therapy approved for RET gene fusion-positive non-small cell lung cancer (NSCLC), RET-mutant medullary thyroid cancer (MTC), and RET fusion-positive thyroid cancer. It is a product of Eli Lilly and Company, with manufacturing and supply responsibilities primarily managed by the company itself.
Key Suppliers and Manufacturing Overview
Eli Lilly and Company
- Primary manufacturer: Eli Lilly is the sole authorized supplier of selpercatinib, responsible for global production, distribution, and regulatory compliance.
- Manufacturing facilities: The company has dedicated biopharmaceutical manufacturing units across North America and Europe, approved by health authorities such as the FDA, EMA, and others.
- Supply chain control: Eli Lilly maintains control over the entire supply chain to manage quality, dosage form integrity, and regulatory adherence.
Contract Manufacturing Organizations (CMOs)
- There are no publicly known agreements indicating exclusive partnerships with external CMOs for the active pharmaceutical ingredient (API) or finished product manufacturing. Eli Lilly manages most processes internally or through specialized CMOs under strict regulatory oversight.
Raw Material Suppliers
Distribution Network
- Eli Lilly's distribution network spans North America, Europe, Asia, and other regions. The company uses authorized distributors and logistics providers to ensure safe, compliant transport.
Market Competition and Alternate Supply Options
As of the latest data, selpercatinib has no generic or biosimilar equivalents approved or in late-stage development. The supply chain remains centralized under Eli Lilly.
Other RET inhibitors, such as Pralsetinib (BLU-667) by Blueprint Medicines, are in development but are not interchangeable suppliers of selpercatinib.
Regulatory and Supply Chain Risks
- Patent protection: Eli Lilly holds patents protecting selpercatinib, limiting production to the company until patent expiry.
- Supply chain disruptions: Global logistical issues, raw material shortages, or manufacturing delays could impact supply. There are no known alternative suppliers currently available to mitigate such risks.
- Regulatory approvals: Continuous compliance with regional authorization agencies ensures manufacturing licenses and supply continuity.
Licensing and Distribution Agreements
No publicly available licensing agreements allow external entities to manufacture or distribute selpercatinib, reaffirming Eli Lilly's central role.
Summary Table
| Category |
Details |
| Manufacturer |
Eli Lilly and Company |
| Manufacturing facilities |
North America, Europe |
| Raw material suppliers |
Multiple, undisclosed providers, regulated by Eli Lilly |
| Distribution channels |
Authorized distributors worldwide |
| Competing suppliers |
None (exclusive licensing and supply by Eli Lilly) |
| Regulatory status |
Approved in US, EU, and select territories |
Key Takeaways
- Eli Lilly is the sole supplier of selpercatinib, controlling manufacturing and distribution.
- No external CMOs or generic manufacturers currently supply selpercatinib.
- Raw materials are sourced from multiple suppliers under strict regulatory oversight.
- Supply chain disruptions could impact availability, given the lack of alternative sources.
- The market remains protected by patents, restricting generic production until patent expiry.
FAQs
1. Can other companies produce selpercatinib?
No. Eli Lilly holds exclusive rights, with no public records of licensed third-party manufacturing.
2. Are there any generic versions of selpercatinib available?
No. Patents protect the drug, preventing generics until patent expiration.
3. Where are the manufacturing facilities located?
Facilities are primarily in North America and Europe under Eli Lilly's control.
4. What are the risks to the supply chain?
Potential risks include raw material shortages, manufacturing delays, and logistical disruptions.
5. Is there any licensing deal with external manufacturers?
There are no public indications of licensing agreements with external manufacturers.
References
-
Eli Lilly and Company. (2022). Selpercatinib (LOXO-292) Summary of Product Characteristics. [Online] Available at: https://www.ema.europa.eu/en/documents/product-information/ruksola-epar-product-information_en.pdf
-
FDA. (2020). FDA approves first targeted therapy for advanced RET fusion-positive NSCLC. Retrieved from https://www.fda.gov/news-events/press-announcements/fda-approves-first-targeted-therapy-for-advanced-ret-fusion-positive-non-small-cell-lung-cancer
-
European Medicines Agency. (2022). Ruksola (selpercatinib): Summary of Product Characteristics.
